Teisha Gene Therapeutics Achieves TSHA-102 Clinical and Manufacturing Milestones
TSHA Taysha Gene Therapies Inc
$4.21 -1.64%
View chart & analysis → - 1Teisha Gene Therapeutics announced that 33 patients treated with TSHA-102 have passed the acute safety monitoring period.
- 2Teisha Gene Therapeutics recorded a net loss of $39.1 million for the three months ended September 30, 2026.
- 3As of September 30, 2026, Teisha Gene Therapeutics' cash and cash equivalents totaled $422.8 million.
So what's the key point?
Teisha Gene Therapeutics reported that 33 patients who received the medication are doing well and are safe. The company had a loss of $39.1 million but still holds cash reserves.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.